G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 14, at 9:30 a.m. PT (12:30 p.m. ET) at the Westin St. Francis Hotel in San Francisco.
To access the live webcast, please visit the within the Investors section of the . The webcast will be archived on the same page for 30 days following the event.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation from the FDA; a rolling NDA submission for small cell lung cancer has begun and is expected to be completed in the second quarter of 2020. is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 Therapeutics also has an active discovery program focused on cyclin-dependent kinase targets.
G1 is based in Research Triangle Park, NC. For additional information, please visit and follow us on Twitter @G1Therapeutics.
Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
